Biovest to give presentation on BiovaxID at San Francisco conference

Biovest.jpg

Biovest, the company behind BiovaxID, the late-stage personalized cancer vaccine for the treatment of indolent non-Hodgkin’s lymphomas such as follicular lymphoma, is announcing that they will be presenting at the upcoming 19th International Molecular Med Tri-Con Cancer Biologics Conference, held February 19–23 at the Moscone Convention Center in San Francisco.

Biovest’s much-anticipated session at the conference is entitled "Vaccination with Patient-Specific Tumor-derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma.”

BiovaxID is not yet been given FDA approval, but if and when it does receive regulatory approval, it would represent the very first non-immunosuppressive consolidation therapy option for patients with follicular lymphoma.

Source: Biovest

LymphomaInfo Social